Pfizer Inc. (PFE) has finalized a global licensing agreement with 3SBio, Inc. to develop and commercialize SSGJ-707, a bispecific antibody for PD-1 and VEGF. The drug is in clinical trials for NSCLC and gynecological tumors, with promising results. Pfizer will pay $1.25 billion upfront and potentially up to $150 million more for exclusive rights in China.

Pfizer Inc. (PFE) aims to focus on Phase 3 studies for NSCLC and other solid tumors by expanding clinical trials globally. This move enhances Pfizer’s oncology pipeline and competitive edge in cancer research. PFE is operating globally and is known for discovering, developing, and selling biopharmaceuticals.

While Pfizer Inc. (PFE) is recognized as one of the best ESG stocks, some believe that certain AI stocks offer greater upside potential with less downside risk. Investors looking for an undervalued AI stock can explore opportunities in the market. For more information on potential investments, consider our free report on the best short-term AI stock.

Read more at Yahoo Finance: Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc.